Department of Pharmaceutics and Biopharmaceutics, University of Marburg, Robert-Koch- Str. 4, 35037 Marburg, Germany; Punjab University College of Pharmacy, University of the Punjab, Allama Iqbal Campus, 54000 Lahore, Pakistan.
Department of Pharmaceutics and Biopharmaceutics, University of Marburg, Robert-Koch- Str. 4, 35037 Marburg, Germany; Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, GC University Faisalabad, Faisalabad, Pakistan.
Int J Pharm. 2020 Dec 15;591:119993. doi: 10.1016/j.ijpharm.2020.119993. Epub 2020 Oct 18.
P-glycoprotein (P-gp) associated multidrug resistance (MDR) represents a major failure in cancer treatment. The overexpression of P-gp is responsible for ATP-dependent efflux of drugs that decrease their intracellular accumulation. An effective downregulation of MDR1 gene using small interfering RNA (siRNA) is one of the safe and effective tools to overcome the P-gp triggered MDR. Therefore, the development of an efficient and non-toxic carrier system for siRNA delivery is a fundamental challenge for effective cancer treatment. Polyamidoamine (PAMAM) dendrimer has been used for efficient delivery of siRNA (dendriplexes) to the tumor cells but the associated toxicity problems render its use in biological applications. A non-covalent lipid modification (lipodendriplexes) is supposed to offer a promising strategy to overcome the demerits linked to the naked dendriplexes system. In the current study, we deliver siRNA, designed against MDR1 gene (si-MDR1), in colorectal carcinoma cells (Caco-2), having overexpression of P-gp, to check the role of MDR1 gene in tumor progression and multidrug resistance using two dimensional (2D) and three dimensional (3D) environment. Imatinib mesylate (IM), a P-gp substrate, was used as model drug. Our results revealed that the effective knockdown by lipodendriplexes system can significantly reduce the tumor cell migration in 2D (p < 0.001) and 3D (p < 0.001) cell cultures as compared to unmodified dendriplexes and si-Control groups. It was also observed that lipodendriplexes aided downregulation of MDR1 gene effectively, re-sensitized the Caco-2 cells for IM uptake and showed a significantly (p < 0.001) higher apoptosis. Our findings imply that our lipodendriplexes system has a great potential for siRNA delivery, however, further in vivo application using a suitable targeted system can play a major role for better cancer therapeutics.
P-糖蛋白(P-gp)相关的多药耐药(MDR)是癌症治疗中的一个主要失败因素。P-gp 的过度表达负责将药物泵出细胞,从而减少其在细胞内的积累。使用小干扰 RNA(siRNA)有效下调 MDR1 基因是克服 P-gp 触发的 MDR 的一种安全有效的方法之一。因此,开发有效的、无毒的 siRNA 递送载体系统是有效癌症治疗的一个基本挑战。聚酰胺-胺(PAMAM)树枝状大分子已被用于将 siRNA(树枝状大分子复合物)高效递送至肿瘤细胞,但相关的毒性问题限制了其在生物应用中的使用。非共价脂质修饰(脂质体复合物)被认为是克服裸树枝状大分子系统缺点的一种有前途的策略。在本研究中,我们将针对 MDR1 基因(si-MDR1)的 siRNA 递送至过表达 P-gp 的结直肠癌细胞(Caco-2)中,以检查 MDR1 基因在肿瘤进展和多药耐药中的作用,使用二维(2D)和三维(3D)环境。伊马替尼甲磺酸盐(IM)是一种 P-gp 底物,被用作模型药物。我们的结果表明,与未经修饰的树枝状大分子复合物和 si-Control 组相比,脂质体复合物系统的有效敲低可显著降低 2D(p<0.001)和 3D(p<0.001)细胞培养物中的肿瘤细胞迁移。还观察到脂质体复合物有效地辅助下调 MDR1 基因,使 Caco-2 细胞重新对 IM 摄取敏感,并表现出显著(p<0.001)更高的细胞凋亡。我们的研究结果表明,我们的脂质体复合物系统具有很大的 siRNA 递送潜力,然而,使用合适的靶向系统进行进一步的体内应用可以在更好的癌症治疗中发挥主要作用。